Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2025)
Historic Non-Current Debt for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $47.6 million.
- Akebia Therapeutics' Non-Current Debt rose 2421.07% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 2421.07%. This contributed to the annual value of $38.7 million for FY2024, which is 12518.19% up from last year.
- Per Akebia Therapeutics' latest filing, its Non-Current Debt stood at $47.6 million for Q3 2025, which was up 2421.07% from $47.1 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Non-Current Debt ranged from a high of $97.2 million in Q3 2021 and a low of $17.2 million during Q4 2023
- Over the past 5 years, Akebia Therapeutics' median Non-Current Debt value was $38.4 million (recorded in 2024), while the average stood at $47.2 million.
- In the last 5 years, Akebia Therapeutics' Non-Current Debt plummeted by 4957.74% in 2023 and then surged by 12518.19% in 2024.
- Akebia Therapeutics' Non-Current Debt (Quarter) stood at $97.2 million in 2021, then crashed by 64.95% to $34.1 million in 2022, then tumbled by 49.58% to $17.2 million in 2023, then skyrocketed by 125.18% to $38.7 million in 2024, then grew by 23.13% to $47.6 million in 2025.
- Its Non-Current Debt stands at $47.6 million for Q3 2025, versus $47.1 million for Q2 2025 and $46.5 million for Q1 2025.